一种新的胆汁酸衍生物的抗神经炎症作用
Srđan Bjedov1, Goran Stegnjaić2, Suzana Stanisavljević2
1Department of Chemistry, Biochemistry, and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia.
International journal of molecular sciences
|July 13, 2024
概括
SB140是一种新型胆汁酸衍生物,有效地激活核因子-氨酸2相关因子2 (Nrf2) 信号. 这种化合物表现出强大的免疫调节作用,在中枢神经系统自身免疫模型中减少炎症.
科学领域:
- 神经免疫学 神经免疫学
- 分子药理学分子药理学
- 药物发现 药物发现 药物发现
背景情况:
- 核因子-红素2相关因子2 (Nrf2) 是抗氧化和抗炎反应的关键调节者.
- 中枢神经系统 (CNS) 自免疫包括免疫细胞活动和炎症的失调.
- 针对神经炎症疾病,需要针对Nrf2的新型治疗策略.
研究的目的:
- 合成和评估SB140,一种新型胆胆酸衍生物,作为一种强大的Nrf2激活剂.
- 在中枢神经系统自身免疫的背景下,研究SB140对微质细胞,骨髓衍生细胞 (MDC) 和T细胞的免疫调节作用.
主要方法:
- 合成SB140,一种胆胆酸衍生物,具有增强的电友功能.
- 在MDC和微质中评估Nrf2信号激活.
- 评估SB140对微质细胞对炎症媒介产生的影响 (氧化,IL-6,TNF).
- 对SB140对脑性T细胞增殖和效应细胞因子 (IL-17,IFN-γ) 生产的影响的分析.
主要成果:
- SB140在髓状细胞和微质细胞中强烈激活了Nrf2信号传递.
- SB140显著降低了微质细胞的炎症性氧化,IL-6和TNF产生.
- SB140抑制了脑性T细胞的增殖及其IL-17和IFN-γ的产生.
- SB140对抗炎性IL-10的产生产生产生了有限的影响.
结论:
- SB140是一种强大的Nrf2激活剂,具有显著的免疫调节特性.
- SB140证明了治疗神经炎症疾病的治疗潜力.
- 需要对多发性硬化症和其他炎症神经系统疾病的动物模型进行进一步的研究.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114


